Lisanti Capital Growth LLC Takes Position in Krystal Biotech, Inc. $KRYS

Lisanti Capital Growth LLC acquired a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 19,050 shares of the company’s stock, valued at approximately $7,080,000. Krystal Biotech makes up about 1.6% of Lisanti Capital Growth LLC’s investment portfolio, making the stock its 12th biggest position. Lisanti Capital Growth LLC owned 0.06% of Krystal Biotech as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in KRYS. Royal Bank of Canada lifted its position in Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after buying an additional 964 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Krystal Biotech by 29.9% in the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock valued at $2,187,000 after acquiring an additional 2,792 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Krystal Biotech by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after acquiring an additional 688 shares during the last quarter. Empowered Funds LLC bought a new stake in Krystal Biotech during the first quarter worth about $218,000. Finally, Cetera Investment Advisers raised its holdings in Krystal Biotech by 107.9% during the second quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock worth $597,000 after acquiring an additional 2,255 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Insiders Place Their Bets

In other news, EVP John Charles Thomas sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the transaction, the executive vice president owned 1,000 shares of the company’s stock, valued at approximately $347,270. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the sale, the insider directly owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 51,642 shares of company stock worth $16,471,923 over the last three months. Insiders own 13.10% of the company’s stock.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $343.34 on Thursday. The company has a market cap of $10.16 billion, a P/E ratio of 43.03 and a beta of 0.53. The firm’s fifty day moving average price is $346.14 and its two-hundred day moving average price is $300.68. Krystal Biotech, Inc. has a one year low of $136.73 and a one year high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, topping the consensus estimate of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The business had revenue of $119.22 million during the quarter, compared to the consensus estimate of $120.93 million. As a group, equities research analysts expect that Krystal Biotech, Inc. will post 7.68 earnings per share for the current year.

Analyst Ratings Changes

KRYS has been the subject of a number of analyst reports. Bank of America raised their price target on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Jefferies Financial Group reissued a “buy” rating and issued a $474.00 price objective on shares of Krystal Biotech in a report on Monday, July 13th. Weiss Ratings cut shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday. Citigroup upped their price target on shares of Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, Chardan Capital raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $365.40.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.